Disease-Associated Anemia: An Integrated Review of Pathophysiology, Diagnosis, and Therapeutic Implications
DOI:
https://doi.org/10.30872/jtpc.v9i2.310Keywords:
anemia, chronic disease, haemoglobinopathy, iron metabolism, bone marrow failureAbstract
Disease-associated anemia is a heterogeneous and prevalent clinical problem, arising from diverse underlying conditions that interfere with erythropoiesis, red blood cell survival, iron metabolism, or blood loss. Major underlying causes include chronic kidney disease, chronic inflammation or infection, malignancy, bone marrow failure syndromes, haemoglobinopathies, autoimmune haemolysis, and chronic blood loss (e.g., gastrointestinal bleeding or parasitic infection). Distinct pathophysiological mechanisms impaired erythrocyte production, increased erythrocyte destruction, and iron sequestration or chronic blood loss often overlap, complicating diagnosis and treatment. Recent advances in understanding molecular regulators such as hepcidin and erythroferrone, and therapeutic innovations including hypoxia-inducible-factor (HIF) stabilizers, hepcidin antagonists, gene therapy for haemoglobinopathies, and refined iron-management protocols, promise improved outcomes. This review synthesizes current evidence on mechanisms, diagnostic approaches, and management strategies across major disease categories causing anemia.
Downloads
References
1. Agarwal, A. K., Kalra, P. A., Kothari, J., Kher, V., & Kalantar-Zadeh, K. (2021). Iron metabolism and management in chronic kidney disease. Kidney International Supplements, 11(1), 56–64. https://doi.org/10.1016/j.kisu.2020.12.003
2. Al-Naseem, A., Sallam, A., Choudhury, S., & Thachil, J. (2021). Iron deficiency without anaemia: A diagnosis that matters. Clinical Medicine, 21(2), 107–113. https://doi.org/10.7861/clinmed.2020-0582
3. Atkinson, J., Safiri, S., & GBD 2021 Anaemia Collaborators. (2025). Getting back on track to meet global anaemia reduction targets: A Lancet Haematology Commission. The Lancet Haematology. https://doi.org/10.1016/S2352-3026(25)00146-2
4. Badura, K., Wieczernik, P., Biernat, J., & Krasowska-Kwiecień, A. (2024). Anemia of chronic kidney disease—A narrative review. Biomedicines, 12(6), 1191. https://doi.org/10.3390/biomedicines12061191
5. Babitt, J. L., & Lin, H-Y. (2012). Mechanisms of anemia in chronic kidney disease. Journal of the American Society of Nephrology, 23(10), 1631–1634. https://doi.org/10.1681/ASN.2011111078
6. Barcellini, W. (2020). New insights in the pathogenesis and treatment of autoimmune hemolytic anemia. Journal of Clinical Medicine, 9(12), 3859. https://doi.org/10.3390/jcm9123859
7. Bhandari, S., Spencer, S., & UK Kidney Association Guideline Group. (2024). UK Kidney Association Clinical Practice Guideline for Anemia of Chronic Kidney Disease. UK Kidney Association.
8. Brooker, S., Hotez, P. J., & Bundy, D. A. P. (2008). Hookworm-related anaemia among pregnant women: A systematic review. PLoS Neglected Tropical Diseases, 2(9), e291. https://doi.org/10.1371/journal.pntd.0000291
9. Camaschella, C. (2019). Iron deficiency. Blood, 133(1), 30–39. https://doi.org/10.1182/blood-2018-05-815944
10. Cappellini, M. D., Comin-Colet, J., de Francisco, A., Dignass, A., Doehner, W., Lam, C. S. P., … Macdougall, I. C. (2017). Iron deficiency across chronic inflammatory conditions: International expert opinion. American Journal of Hematology, 92(10), 1068–1078. https://doi.org/10.1002/ajh.24820
11. D’Angelo, G. (2013). Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood Research, 48(1), 10–15. https://doi.org/10.5045/br.2013.48.1.10
12. de las Cuevas Allende, R., Entrenas-Cortés, J., & Díez, J.-M. (2021). Anaemia of chronic diseases: Pathophysiology, diagnosis and treatment. Best Practice & Research Clinical Haematology, 34(3), 101–113. https://doi.org/10.1016/j.beha.2020.101113
13. Fenwick, A. (2012). The global burden of neglected tropical diseases. Public Health, 126(3), 233–236. https://doi.org/10.1016/j.puhe.2011.11.015
14. Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y-S., Domm, J., Eustace, B. K., … Corbacioglu, S. (2021). CRISPR-CAS9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 384(3), 252–260. https://doi.org/10.1056/NEJMoa2031054
15. Garbe, E., Andersohn, F., Bronder, E., Klimpel, A., Thomae, M., Schrezenmeier, H., … Salama, A. (2011). Drug-induced immune haemolytic anaemia. British Journal of Haematology, 154(5), 644–653. https://doi.org/10.1111/j.1365-2141.2011.08784.x
16. GBD 2021 Anaemia Collaborators. (2023). Global burden and trends in anaemia, 1990–2021. The Lancet Haematology, 10(7), e489–e514. https://doi.org/10.1016/S2352-3026(23)00160-6
17. Hotez, P. J., & Kamath, A. (2009). Neglected tropical diseases in sub-Saharan Africa. PLoS Neglected Tropical Diseases, 3(8), e412. https://doi.org/10.1371/journal.pntd.0000412
18. Kanter, J., Walters, M. C., Krishnamurti, L., Mapara, M. Y., Kwiatkowski, J. L., Abraham, A., … Esrick, E. B. (2022). Biologic efficacy of LentiGlobin for sickle cell disease. New England Journal of Medicine, 386(7), 617–628. https://doi.org/10.1056/NEJMoa2117175
19. Kassebaum, N. J., Jasrasaria, R., Naghavi, M., Wulf, S. K., Johns, N., Lozano, R., … Murray, C. J. L. (2014). A systematic analysis of global anemia burden. Blood, 123(5), 615–624. https://doi.org/10.1182/blood-2013-06-508325
20. KDIGO Anemia Work Group. (2021). KDIGO 2021 Clinical Practice Guideline for Anemia in CKD. Kidney International Supplements, 11(1), 1–142.
21. Kroot, J. J. C., Tjalsma, H., Fleming, R. E., & Swinkels, D. W. (2011). Hepcidin in human iron disorders: Diagnostic implications. Clinical Chemistry, 57(12), 1650–1669. https://doi.org/10.1373/clinchem.2009.140053
22. Kulik-Rechberger, B., Marchewka, Z., & Rechberger, T. (2024). Iron deficiency and anemia of inflammation. Annals of Agricultural and Environmental Medicine, 31(1), 19–27. https://doi.org/10.26444/aaem/171121
23. Langer, A. L., & Ginzburg, Y. Z. (2017). Hepcidin–ferroportin axis in anemia of chronic inflammation. Hematology, 22(8), 607–616. https://doi.org/10.1080/10245332.2017.1329488
24. Menendez, C., Fleming, A. F., & Alonso, P. L. (2000). Malaria-related anemia. Parasitology Today, 16(11), 469–476. https://doi.org/10.1016/S0169-4758(00)01774-9
25. Mishra, A. K., & Tiwari, A. (2013). Iron overload in β-thalassemia. Maedica, 8(4), 328–332.
26. Morceau, F., Dicato, M., & Diederich, M. (2009). Cytokine-mediated anemia. Mediators of Inflammation, 2009, 405016. https://doi.org/10.1155/2009/405016
27. National Comprehensive Cancer Network. (2024). NCCN Guideline: Cancer- and Chemotherapy-Induced Anemia (Version 1.2024). NCCN.
28. Nemeth, E., & Ganz, T. (2022). Hepcidin and iron in health and disease. Annual Review of Medicine, 73, 527–540. https://doi.org/10.1146/annurev-med-042220-020836
29. Öneç, K., Altun, G., Özdemir Aytekin, Ş., Davran, F., & Öneç, B. (2025). ERFE, hepcidin and erythropoietin in CKD. Journal of Clinical Medicine, 14(21), 7789. https://doi.org/10.3390/jcm14217789
30. Pfeffer, M. A., Burdmann, E. A., Chen, C-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K-U., … Parfrey, P. (2009). Darbepoetin alfa in type 2 diabetes and CKD. New England Journal of Medicine, 361(21), 2019–2032. https://doi.org/10.1056/NEJMoa0907845
31. Pinto, V. M., & Forni, G. L. (2020). Management of iron overload in β-thalassemia. International Journal of Molecular Sciences, 21(22), 8771. https://doi.org/10.3390/ijms21228771
32. Provenzano, R., Besarab, A., Sun, C-H., Diamond, S. A., Durham, J. H., Cangiano, J. L., … Macdougall, I. C. (2016). Oral HIF-PH inhibitor roxadustat for anemia in CKD. Clinical Journal of the American Society of Nephrology, 11(6), 982–991. https://doi.org/10.2215/CJN.06820615
33. Safiri, S., Kolahi, A-A., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., … Vos, T. (2021). Burden of anemia in 204 countries. Journal of Hematology & Oncology, 14, 185. https://doi.org/10.1186/s13045-021-01202-2
34. Sangkhae, V., & Nemeth, E. (2017). Regulation of hepcidin. Advances in Nutrition, 8(1), 126–136. https://doi.org/10.3945/an.116.013961
35. Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006). Correction of anemia with epoetin alfa. New England Journal of Medicine, 355(20), 2085–2098. https://doi.org/10.1056/NEJMoa065485
36. Soares, M. P., & Weiss, G. (2015). The iron age of host–microbe interactions. EMBO Reports, 16(11), 1482–1500. https://doi.org/10.15252/embr.201540425
37. Steinbicker, A. U., & Muckenthaler, M. U. (2013). Systemic iron homeostasis in iron disorders. Nutrients, 5(8), 3034–3061. https://doi.org/10.3390/nu5083034
38. Taher, A. T., Musallam, K. M., & Cappellini, M. D. (2021). β-Thalassemias. New England Journal of Medicine, 384(8), 727–743. https://doi.org/10.1056/NEJMra2021838
39. Townsley, D. M., Dumitriu, B., & Young, N. S. (2014). Aplastic anemia diagnosis and treatment. Mayo Clinic Proceedings, 89(11), 1645–1659. https://doi.org/10.1016/j.mayocp.2014.07.010
40. Weatherall, D. J. (2010). Thalassemia as a global health problem. Annals of the New York Academy of Sciences, 1202(1), 17–23. https://doi.org/10.1111/j.1749-6632.2010.05546.x
41. Weatherall, D. J. (2011). The inherited disorders of haemoglobin. Indian Journal of Medical Research, 134(4), 493–497.
42. Weiss, G., Ganz, T., & Goodnough, L. T. (2019). Anemia of inflammation. Blood, 133(1), 40–50. https://doi.org/10.1182/blood-2018-06-856500
43. Wiciński, M., Liczner, G., Cadelski, K., Kołnierzak, T., Nowaczewska, M., & Malinowski, B. (2020). Anemia of chronic diseases: Wider diagnostics. Nutrients, 12(6), 1784. https://doi.org/10.3390/nu12061784
44. World Health Organization. (2020). WHO guideline on the use of ferritin concentrations to assess iron status. WHO.
45. World Health Organization. (2024). Haemoglobin concentrations for diagnosing anaemia and assessing severity: 2024 update. WHO.
46. Young, N. S. (2018). Aplastic anemia. New England Journal of Medicine, 379(17), 1643–1656. https://doi.org/10.1056/NEJMra1413485
47. Pinto, V. M., & Forni, G. L. (2020). Management of iron overload in beta-thalassemia. International Journal of Molecular Sciences, 21(22), 8771. https://doi.org/10.3390/ijms21228771
48. Provenzano, R., Besarab, A., Sun, C-H., Diamond, S. A., Durham, J. H., Cangiano, J. L., … Macdougall, I. C. (2016). Roxadustat in anemia associated with CKD. Clinical Journal of the American Society of Nephrology, 11(6), 982–991. https://doi.org/10.2215/CJN.06820615
49. Pinto, V. M., & Forni, G. L. (2020). Management of iron overload. International Journal of Molecular Sciences, 21(22), 8771. https://doi.org/10.3390/ijms21228771
50. World Health Organization. (2024). Haemoglobin concentrations for the diagnosis of anaemia: 2024 update. WHO.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Nanny Djaya, Irene Vanessa, Christina Jeanny (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
